Tang Siu Wa, Helmeste Daiga
University of California, Psychiatry North Campus Zot 1681, Irvine, California 92697-1681, USA.
Expert Opin Pharmacother. 2008 Apr;9(5):787-94. doi: 10.1517/14656566.9.5.787.
Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients.
The purpose of this paper is to review the pharmacology, efficacy and safety of paroxetine in the affective disorders.
The authors performed a PubMed search for all literature in English crossing the words 'paroxetine' and 'Paxil' against the words 'serotonin transporter,' 'clinical trials,' 'depression' and 'SSRI'. A search for paroxetine-related information at the FDA website and under the clinical trial register of the GSK website were also performed.
RESULTS/CONCLUSION: Paroxetine is a serotonin re-uptake inhibitor with good selectivity and no significant active metabolites. Paroxetine is approved (ages >or= 18 years) for the treatment of major depressive disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder (social phobia), post-traumatic stress disorder, and generalized anxiety disorders. Drug - drug interactions involving the CYP enzyme system have been documented, as well as concern for increased suicidality risk in younger adults and recent FDA alerts regarding teratogenicity, serotonin syndrome and persistent pulmonary hypertension.
帕罗西汀是一种广泛使用的抗抑郁药，其在年轻患者中的自杀风险受到关注。
本文旨在综述帕罗西汀在情感障碍中的药理学、疗效和安全性。
作者在PubMed上检索了所有英文文献，搜索词为“帕罗西汀”和“帕罗西汀片”，对照词为“5-羟色胺转运体”、“临床试验”、“抑郁症”和“选择性5-羟色胺再摄取抑制剂”。还在FDA网站以及葛兰素史克公司网站的临床试验注册库中搜索了与帕罗西汀相关的信息。
结果/结论：帕罗西汀是一种5-羟色胺再摄取抑制剂，具有良好的选择性，且无明显活性代谢产物。帕罗西汀已被批准（年龄≥18岁）用于治疗重度抑郁症、恐慌症、强迫症、社交焦虑症（社交恐惧症）、创伤后应激障碍和广泛性焦虑症。已记录到涉及CYP酶系统的药物相互作用，以及对年轻成年人自杀风险增加的担忧，近期FDA还发布了关于致畸性、5-羟色胺综合征和持续性肺动脉高压的警示。
